demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
anticoagulant
anticoagulant, curative dose ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose RAPID ...

2 studies excluded by filtering options 0

5895 X-COVID-19, 2021 010selection pending
10523 FREEDOM COVID, 2023 010selection pending